BPI 9220
Alternative Names: BPI-9220Latest Information Update: 18 Aug 2021
At a glance
- Originator Beta Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 04 Aug 2021 BPI 9220 is available for licensing as of 04 Aug 2021. http://betapharma.com/about-us/oncology-drug-development/
- 04 Aug 2021 Early research in Solid tumours in USA (unspecified route) (Beta Pharma pipeline, August 2021)